Loading…
No business profile yet.
Size Symbiotec Pharmalab (SYMBIOTEC.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 583rd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,514 on 6 Nov 2026.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | ₹7.36B | ₹7.00B | ₹5.51B |
| Revenue growth | — | — | +5% | +27% | — |
| Gross profit | n/a | n/a | ₹2.04B | ₹1.73B | ₹788M |
| EBITDA | n/a | n/a | ₹1.91B | ₹1.60B | ₹592M |
| Net income | n/a | n/a | ₹968M | ₹1.00B | ₹235M |
| Free cash flow | n/a | n/a | -₹2.75B | -₹290M | -₹1.61B |
| Capital expenditure | n/a | n/a | ₹3.08B | ₹2.10B | ₹2.24B |
| Total debt | n/a | n/a | ₹5.44B | ₹2.51B | ₹2.20B |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYMBIOTEC.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +33.3% | -3.4% | highest of 21 |
| Distance from 52-week high | -0.8% | -32.2% | highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 1.3× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | 5.0× | 11.9% | -13.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 1.2× | 1.5% | +12.1% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 8.3× | -9.5% | +18.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 1.8× | -6.4% | -7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 1.5× | 3.4% | +1.8% |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 4.4× | 51.8% | +41.0% |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | 1.9× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 1.0× | -9.4% | -7.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 3.0× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | 3.0× | 8.8% | -6.9% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | 68.9× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 3.2× | -5.7% | +12.7% |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 3.2× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | 14.8× | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | 4.7× | 34.1% | -6.0% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 2.3× | 2.1% | -0.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 2.4× | 5.0% | +3.5% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 5.5× | 10.2% | +13.4% |